2016/11/28 by Hartmut Döhner, Elihu H. Estey, David Grimwade +19 · 3 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Acute Myeloid Leukemia Research #Histone Deacetylase Inhibitors Research #Chronic Myeloid Leukemia Treatments #Medicine #Expert opinion #Minimal residual disease #Genetic testing #Disease #Myeloid leukemia #Intensive care medicine #Oncology #Family medicine #Leukemia #Internal medicine
paper · pdf · doi:10.1182/blood-2016-08-733196
openalex publication_date 2016/11/28 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/05
The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.